Company intelligence / Profile preview
ActoKine Therapeutics
Chestnut Hill, MA, USAactokine.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Commercial
01
Overview
ActoKine Therapeutics has two lead programs, AK‑1 for radioprotection in cancer therapy and AK‑2 for virus prevention, both in late preclinical development. The company focuses on discovering new functions of existing drugs (drug rescue/indication switch) and novel biologics to protect normal cells while selectively targeting tumor or virus-infected cells. No clinical results have been published as of June 2025[1][3][4].
- Therapeutic areas
- OncologyInfectious DiseasesEndocrinologyNeurologyWomen's Health
- Modalities
- Synthetic peptideSmall moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on ActoKine Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ActoKine Therapeutics.